How to Help Your Patients Find Pregabalin in Stock: A Provider's Guide

Patients on long-term pregabalin therapy for diabetic neuropathy, fibromyalgia, postherpetic neuralgia, or epilepsy occasionally find themselves unable to fill a prescription at their usual pharmacy. While pregabalin is not in a national shortage as of 2026, pharmacy-level stock variability is real — and the risks of abrupt discontinuation are serious enough that providers should have a clear response protocol ready.

This guide provides actionable steps your practice can take to help patients locate their medication quickly and safely, and what to do when the drug genuinely cannot be found.

Why Patients Struggle to Fill Pregabalin Even Without a Shortage

Understanding the cause helps guide the solution. Patients typically struggle because of:

• Strength-specific stock-outs: A pharmacy may have 75 mg capsules in stock but not 150 mg or 300 mg.
• DEA Schedule V ordering rules: Controlled substance restocking is more regulated than for unscheduled drugs, which can extend the wait when a specific strength is backordered.
• Generic manufacturer variability: Different pharmacies source from different manufacturers. A patient's preferred pharmacy may be out while another nearby has full stock.
• Insurance and cost barriers: Coverage or prior authorization issues may prevent filling even when stock is available.

Step 1: Counsel Patients to Refill Early

The most effective intervention is proactive. Counsel patients on pregabalin to:

• Request refills 5–7 days before running out (consistent with Schedule V refill timing rules in most states)
• Contact the practice immediately — not the day they run out — if they encounter difficulty finding the medication
• Understand that abrupt discontinuation is medically risky and should never happen without contact with their provider

Step 2: Consider Writing for a Different Strength

If a specific capsule strength is unavailable, consider whether an equivalent can be achieved with available strengths. Common substitutions:

• 150 mg BID → two 75 mg capsules BID (same total daily dose)
• 300 mg BID → two 150 mg capsules BID or four 75 mg capsules BID
• Capsules unavailable → 20 mg/mL oral solution may be an option (verify insurance coverage first)

Always call the pharmacy to confirm that the alternative strength is actually in stock before writing a new prescription to save the patient a wasted trip.

Step 3: Direct Patients to Tools That Do the Legwork

One of the most effective resources you can share with patients is medfinder for providers. medfinder contacts pharmacies near the patient's location to check which ones have their specific medication and dose in stock, then texts the patient with results — eliminating the patient's need to call pharmacy after pharmacy. For patients dealing with a temporary stock-out, this can reduce the time to resolution from hours to minutes.

Consider printing or emailing this resource to patients when you prescribe pregabalin, so they have it ready before they need it.

Step 4: Address Insurance and Prior Authorization Barriers

Some patients who report difficulty filling pregabalin are actually encountering insurance barriers rather than stock problems. Key issues to check:

• Formulary tier: Generic pregabalin is generally Tier 2 on most plans, but formularies change annually. A plan that covered it in 2025 may have changed its tier or quantity limits for 2026.
• Quantity limits: Some plans limit the monthly quantity of Schedule V controlled substances. If the prescription exceeds the plan's limit, a prior authorization or exception may be needed.
• Brand vs. generic coverage: If a patient is on brand-name Lyrica, their plan may have changed coverage; a switch to generic pregabalin is therapeutically equivalent and typically far less expensive.

Step 5: Have an Alternative Ready If Needed

For patients who genuinely cannot access pregabalin, having a plan B avoids dangerous gaps in treatment. See our companion article Pregabalin Shortage: What Providers and Prescribers Need to Know in 2026 for detailed guidance on therapeutic alternatives by indication.

Key Takeaways for Providers

• Pregabalin is not in a national shortage — most stock issues are pharmacy-level and temporary
• Abrupt discontinuation is dangerous — patients must be counseled to report difficulty filling before they run out
• Strength reformulation (different capsule strengths combining to same daily dose) solves many stock problems
• Tools like medfinder help patients navigate pharmacy availability without hours on hold
• Insurance barriers are common — check formulary tier, quantity limits, and prior auth requirements when patients report trouble filling